Q-omics provides the consensus-scored OTUD5 profile across patient tissues and cancer cell-line models. OTUD5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, OTUD5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, OTUD5 RNA expression shows 18,698 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SCLC, HNSC, and KIRP as cancer lineages where OTUD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTUD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTUD5 survival associations across molecular data types. OTUD5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTUD5 RNA expression–survival associations across cancer types. High OTUD5 expression shows unfavorable associations in KICH, COAD and LIHC, but favorable associations in SCLC, THYM and SKCM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for OTUD5 RNA expression.
This table summarizes OTUD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for OTUD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTUD5 shows lower tumor expression in UCEC and higher tumor expression in HNSC, COAD, LIHC, KIRP and CHOL. The HNSC box plot shows higher OTUD5 RNA expression in tumor versus normal tissue (log2 FC = +0.551, t-test p < 0.001).
This table shows molecular features associated with OTUD5 in patient tissues and cancer cell lines. In patient samples, OTUD5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, OTUD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
